Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD-EXT long-term odevixibat extension study in children with biliary atresia
NL-OMON59900Phase 3Recruiting
- Sponsor
- Ipsen
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of odevixibat in biliary atresia, sponsored by Ipsen. Primary endpoint: Time to liver transplant or death. Started Mar 2023; status: recruiting.
02
Drugs
odevixibat
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NL-OMON59900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59900.